Media centre


Fact sheet
Updated March 2018

Key facts

  • There are 3 main forms of leishmaniases – visceral (also known as kala-azar and the most serious form of the disease), cutaneous (the most common), and mucocutaneous.
  • Leishmaniasis is caused by the protozoan Leishmania parasites which are transmitted by the bite of infected female phlebotomine sandflies.
  • The disease affects some of the poorest people on earth, and is associated with malnutrition, population displacement, poor housing, a weak immune system and lack of financial resources.
  • Leishmaniasis is linked to environmental changes such as deforestation, building of dams, irrigation schemes, and urbanization.
  • An estimated 700 000 to 1 million new cases and 20 000 to 30 000 deaths occur annually.
  • Only a small fraction of those infected by Leishmania parasites will eventually develop the disease.

Leishmaniasis is caused by a protozoa parasite from over 20 Leishmania species. Over 90 sandfly species are known to transmit Leishmania parasites. There are 3 main forms of the disease:

  • Visceral leishmaniasis (VL), also known as kala-azar is fatal if left untreated in over 95% of cases. It is characterized by irregular bouts of fever, weight loss, enlargement of the spleen and liver, and anaemia. Most cases occur in Brazil, East Africa and in South-East Asia. An estimated 50 000 to 90 000 new cases of VL occur worldwide each year. In 2015, more than 90% of new cases reported to WHO occurred in 7 countries: Brazil, Ethiopia, India, Kenya, Somalia, South Sudan and Sudan.
  • Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis and causes skin lesions, mainly ulcers, on exposed parts of the body, leaving life-long scars and serious disability. About 95% of CL cases occur in the Americas, the Mediterranean basin, the Middle East and Central Asia. In 2015 over two thirds of new CL cases occurred in 6 countries: Afghanistan, Algeria, Brazil, Colombia, Iran (Islamic Republic of) and the Syrian Arab Republic. It is estimated that between 600 000 to 1 million new cases occur worldwide annually.
  • Mucocutaneous leishmaniasis leads to partial or total destruction of mucous membranes of the nose, mouth and throat. Over 90% of mucocutaneous leishmaniasis cases occur in Bolivia (the Plurinational State of), Brazil, Ethiopia and Peru.


Leishmania parasites are transmitted through the bites of infected female phlebotomine sandflies. The epidemiology of leishmaniasis depends on the characteristics of the parasite species, the local ecological characteristics of the transmission sites, current and past exposure of the human population to the parasite, and human behaviour. Some 70 animal species, including humans, have been found as natural reservoir hosts of Leishmania parasites.

WHO regional specificities

WHO African Region

Visceral, cutaneous and mucocutaneous leishmaniasis are endemic in Algeria and countries in East Africa which are highly endemic. In East Africa, outbreaks of visceral leishmaniasis occur frequently.

WHO Region of the Americas

The epidemiology of cutaneous leishmaniasis in the Americas is very complex, with variations in transmission cycles, reservoir hosts, sandfly vectors, clinical manifestations and response to therapy, and multiple circulating Leishmania species in the same geographical area. Brazil represents over 90% of the VL cases in that region.

WHO Eastern Mediterranean Region

This region accounts for 70% of the cutaneous leishmaniasis cases worldwide. Visceral leishmaniasis is highly endemic in Iraq, Somalia and Sudan.

WHO European Region

Cutaneous and visceral leishmaniasis are endemic in this region. There are also imported cases mainly from Africa and the Americas.

WHO South-East Asia Region

Visceral leishmaniasis is the main form of the disease in this region, also endemic for cutaneous leishmaniasis. The region is the only one with a regional initiative to eliminate visceral leishmaniasis as a public health problem.

Post-kala-azar dermal leishmaniasis (PKDL)

Post-kala-azar dermal leishmaniasis (PKDL) is usually a sequel of visceral leishmaniasis that appears as macular, papular or nodular rash usually on face, upper arms, trunks and other parts of the body. It occurs mainly in East Africa and on the Indian subcontinent, where 5–10% of patients with kala-azar develop the condition. It usually appears 6 months to 1 or more years after kala-azar has apparently been cured, but can occur earlier. People with PKDL are considered to be a potential source of kala-azar infection.

Leishmania-HIV co-infection

Leishmania-HIV coinfected people have high chance of developing the full-blown clinical disease, and high relapse and mortality rates. Antiretroviral treatment reduces the development of the disease, delays relapses and increases the survival of the coinfected patients. High Leishmania-HIV coinfection rates are reported from Brazil, Ethiopia and the state of Bihar in India.

Major risk factors

Socioeconomic conditions

Poverty increases the risk for leishmaniasis. Poor housing and domestic sanitary conditions (such as a lack of waste management or open sewerage) may increase sandfly breeding and resting sites, as well as their access to humans. Sandflies are attracted to crowded housing as these provide a good source of blood-meals. Human behaviour, such as sleeping outside or on the ground, may increase risk.


Diets lacking protein-energy, iron, vitamin A and zinc increase the risk that an infection will progress to kala-azar.

Population mobility

Epidemics of both cutaneous and visceral leishmaniasis are often associated with migration and the movement of non-immune people into areas with existing transmission cycles. Occupational exposure as well as widespread deforestation remain important factors.

Environmental changes

The incidence of leishmaniasis can be affected by changes in urbanization, and the human incursion into forested areas.

Climate change

Leishmaniasis is climate-sensitive.and affect the epidemiology of leishmaniasis in a number of ways:

  • changes in temperature, rainfall and humidity can have strong effects on vectors and reservoir hosts by altering their distribution and influencing their survival and population sizes;
  • small fluctuations in temperature can have a profound effect on the developmental cycle of Leishmania promastigotes in sandflies, allowing transmission of the parasite in areas not previously endemic for the disease;
  • drought, famine and flood can lead to massive displacement and migration of people to areas with transmission of Leishmania, and poor nutrition could compromise their immunity.

Diagnosis and treatment

In visceral leishmaniasis, diagnosis is made by combining clinical signs with parasitological, or serological tests (such as rapid diagnostic tests). In cutaneous and mucocutaneous leishmaniasis serological tests have limited value and clinical manifestation with parasitological tests confirms the diagnosis.

The treatment of leishmaniasis depends on several factors including type of disease, concomitant pathologies, parasite species and geographic location. Leishmaniasis is a treatable and curable disease, which requires an immunocompetent system because medicines will not get rid of the parasite from the body, thus the risk of relapse if immunosuppression occurs. All patients diagnosed as with visceral leishmaniasis require prompt and complete treatment. Detailed information on treatment of the various forms of the disease by geographic location is available in the WHO technical report series 949, "Control of leishmaniasis".

Prevention and control

Prevention and control of leishmaniasis requires a combination of intervention strategies because transmission occurs in a complex biological system involving the human host, parasite, sandfly vector and in some causes an animal reservoir host. Key strategies for prevention are listed below:

  • Early diagnosis and effective treatment reduces the prevalence of the disease and prevents disabilities and death. Early detection and prompt treatment of cases help to reduce transmission and to monitor the spread and burden of disease. Currently there are highly effective and safe anti-leishmanial medicines particularly for visceral leishmaniasis. Access to these medicines has significantly improved thanks to a WHO-negotiated price scheme and a medicine donation programme through WHO.
  • Vector control helps to reduce or interrupt transmission of disease by controlling sandflies. Control methods include insecticide spray, use of insecticide–treated nets, environmental management and personal protection.
  • Effective disease surveillance is important to promptly monitor and take action during epidemics and situations with high case fatality rates under treatment.
  • Control of animal reservoir hosts is complex and should be tailored to the local situation.
  • Social mobilization and strengthening partnerships – mobilization and education of the community with effective behavioural change interventions must always use locally tailored communication strategies. Partnership and collaboration with various stakeholders and other vector-borne disease control programmes is critical.

WHO response

WHO's work on leishmaniasis control involves:

  • Supporting national leishmaniasis control programmes technically and financially to produce updated guidelines and make disease control plans, including sustainable, effective surveillance systems, and epidemic preparedness and response systems.
  • Monitoring disease trends and assessing the impact of control activities which will allow raising awareness and advocacy on the global burden of leishmaniasis, and promoting equitable access to health services.
  • Developing evidence-based policy guidelines, strategies and standards for leishmaniasis prevention and control, and monitoring their implementation.
  • Strengthening collaboration and coordination among partners, stakeholders and other bodies.
  • Promoting research and use of effective leishmaniasis control including safe, effective and affordable medicines, as well as diagnostic tools and vaccines.